Maybe just random noise, and anything above 700 mg

Maybe just random noise, and anything above 700 mg works to lower nasopharyngeal viral load quicker. Most important result is in high risk subjects ~15% on placebo went to hospital vs. only ~5% getting any dose of bamlanivimab. Here are the interim results that led to EUA:

https://www.nejm.org/doi/full/10.1056/NEJMoa2029849

Overall it was 6.3% placebo reduced to 1.6% for any dose of bamlan. The problem in mild-to-moderate as CYDY's trial showed, is that most get better on their own, so hard to show an effect. Number needed to treat to save one visit to the hospital is pretty high. They don't even talk about how those subjects did while in the hospital. Could be there is no difference, so was much really gained? Have to stay tuned for further results, if FDA requires it.

Bamlan was canceled for moderate to severe subjects since no benefit there.

It makes sense that antivirals needed for treatment in viral stage of disease, and immunomodulators like leronlimab for the hyperimmune, later stages.

Even with vaccines and viral treatments, there will still be some that reach the later, hyperimmune stage and will need an effective immunomodulatory drug like leronlimab.

Huge overreactions all across the market today.